Xtant Medical Q3 revenue $27.9M (+12% YoY); reaffirms FY2024 guidance $116-120M

Xtant Medical Holdings, Inc.

2024-Q3 EPS reported -$0.10 revenue$85,754,000

Revenue $27.9M (+12% YoY); YTD revenue $85.8M (+36% YoY).
Net loss $5.0M vs net income $9.2M in Q3 2023, which included $11M bargain purchase gain.
Adjusted EBITDA loss $196K vs $440K gain; gross margin 58.4% down from 61.3%.
Reaffirmed FY2024 revenue guidance $116-120M, representing 27-31% annual growth.
Launched OsteoVive+ and Cortera system; signed license agreement for minimum $5.25M in fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.